Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28429553 | 0.85 | TSHR (0.36) | TSHR | |
| SCHEMBL18422774 | 0.85 | TSHR (0.36) | TSHR | |
| SCHEMBL7569413 | 0.78 | HMGCR (0.40) | — | |
| SCHEMBL5517525 | 0.78 | HMGCR (0.40) | — | |
| SCHEMBL4195332 | 0.78 | HMGCR (0.40) | — | |
| SCHEMBL6775172 | 0.78 | HMGCR (0.40) | — | |
| SCHEMBL690606 | 0.75 | TSHR (0.34) | TSHR | |
| SCHEMBL19206680 | 0.73 | — | — | |
| SCHEMBL11010189 | 0.72 | HMGCR (0.36) | — | |
| SCHEMBL2120933 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116963761-A | Small molecule antagonists against relaxin-3/RXFP 3 system | 研究三角协会 | 2023-10-27 | — | — | CN | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2144614-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY USING TETRACYCLINE COMPOUNDS | Paratek Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008127722-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY USING TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TSHR 4191/4885PTGS2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.